Tory Anne Eisenlohr-Moul

Dr. Tory Anne Eisenlohr-Moul

Auto-generated profile, based on publicly available information

Dr. Tory Anne Eisenlohr-Moul


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Psychoneuroendocrinology
Verified
Journal Article
Closed access
KSKatja Schmalenberger
Katja Schmalenberger
HTHafsah A. Tauseef
Hafsah A. Tauseef
JBJordan C. Barone
Jordan C. Barone
SOSarah A. Owens
Sarah A. Owens
LLLynne Lieberman
Lynne Lieberman
TETory A. Eisenlohr-Moul
Tory A. Eisenlohr-Moul


1 September 2013 in Psychological Bulletin
Verified
Journal Article
Closed access
ADAaron A. Duke
Aaron A. Duke
LBLaurent Bègue
Laurent Bègue
RBRob Bell
Rob Bell
TETory Eisenlohr-Moul
Tory Eisenlohr-Moul
The inverse relation between serotonin and human aggression is often portrayed as "reliable," "strong," and "well established" despite decades of conflicting reports and widely recognized methodological limitations. In this systematic review and meta-analysis, we evaluate the evidence for and against the serotonin deficiency hypothesis of human aggression across 4 methods of assessing serotonin: (a) cerebrospinal fluid levels of 5-hydroxyindoleacetic acid (CSF 5-HIAA), (b) acute tryptophan depletion, (c) pharmacological challenge, and (d) endocrine challenge. Results across 175 independent samples and over 6,500 total participants were heterogeneous, but, in aggregate, revealed a small, inverse correlation between serotonin functioning and aggression, anger, and hostility (r = -.12). Pharmacological challenge studies had the largest mean weighted effect size (r = -.21), and CSF 5-HIAA studies had the smallest (r = -.06). Potential methodological and demographic moderators largely failed to account for variability in study outcomes. Notable exceptions included year of publication (effect sizes tended to diminish with time) and self- versus other-reported aggression (other-reported aggression was positively correlated to serotonin functioning). We discuss 4 possible explanations for the pattern of findings: unreliable measures, ambient correlational noise, an unidentified higher order interaction, and a selective serotonergic effect. Finally, we provide 4 recommendations for bringing much needed clarity to this important area of research: acknowledge contradictory findings and avoid selective reporting practices; focus on improving the reliability and validity of serotonin and aggression measures; test for interactions involving personality and/or environmental moderators; and revise the serotonin deficiency hypothesis to account for serotonin's functional complexity.

1 July 2012 in Clinical Psychology Review
Verified
Journal Article
Closed access
RBRuth A. Baer
Ruth A. Baer
JPJessica R. Peters
Jessica R. Peters
TETory A. Eisenlohr-Moul
Tory A. Eisenlohr-Moul
PGPaul J. Geiger
Paul J. Geiger
SSShannon E. Sauer
Shannon E. Sauer

1 March 2016 in Menopause
Verified
Journal Article
Closed access
JGJennifer L. Gordon
Jennifer L. Gordon
DRDavid R. Rubinow
David R. Rubinow
TETory A. Eisenlohr-Moul
Tory A. Eisenlohr-Moul
JLJane Leserman
Jane Leserman
SGSusan S. Girdler
Susan S. Girdler
Objective: The aim of the study was to examine the role of estradiol fluctuation in triggering depressive symptoms in the menopausal transition and assess the role of recent very stressful life events (VSLEs) as a moderating factor in this relationship. Methods: A total of 52 euthymic women in the menopausal transition or early postmenopause (age 45-60) who were assigned to the placebo arm of a randomized controlled trial of hormone therapy provided the data for this report. At enrollment, women's experience of recent VSLEs, depressive symptoms, serum estradiol, and progesterone were assessed. At months 1, 8, and 14, depressive symptoms and hormones were reassessed, and participants underwent a stressor battery involving a speech and a mental arithmetic task. Participants rated their feelings of anxiety, fear, anger, and rejection. The standard deviation of estradiol provided an index of hormone variability over the entire 14 months. Results: Greater estradiol variability across the 14 months predicted greater depressive symptoms at month 14, though only in women reporting a higher number of VSLEs at baseline (39% of women reported ≤1 recent event). Greater estradiol variability also predicted greater feelings of rejection to the laboratory stressor at months 8 and 14. Furthermore, among women reporting higher VSLEs at baseline, feelings of rejection in response to the laboratory stressor at month 8 predicted depressive symptoms at month 14. Conclusions: These data suggest that estradiol variability may enhance emotional sensitivity to psychosocial stress, particularly sensitivity to social rejection. Combined with VSLEs proximate to the menopausal transition, this increased sensitivity may contribute to the development of depressed mood.

12 November 2019 in Journal of Clinical Medicine
Verified
Journal Article
Open access
KSKatja Schmalenberger
Katja Schmalenberger
TETory A. Eisenlohr-Moul
Tory A. Eisenlohr-Moul
LWLena Würth
Lena Würth
ESEkaterina Schneider
Ekaterina Schneider
JTJulian F. Thayer
Julian F. Thayer
MJMarc Jarczok
Marc Jarczok
Interest in cardiac vagal activity (CVA; e.g., parasympathetically-mediated heart rate variability) as a biomarker of physical and mental health has increased exponentially in recent years. However, the understanding of sources of within-person change (i.e., intra-individual variance) in CVA is lagging behind. This systematic review and meta-analysis summarizes and quantifies current empirical evidence of within-person changes in measures of CVA across the menstrual cycle in naturally-cycling premenopausal females. We conducted an extensive literature search following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement in five databases to identify observational studies with repeated measures of CVA in at least two menstrual cycle phases. A broad meta-analysis (nstudies = 37; nindividuals = 1,004) revealed a significant CVA decrease from the follicular to luteal phase (d = −0.39, 95% CI (−0.67, −0.11)). Furthermore, 21 studies allowed for finer-grained comparisons between each of two cycle phases (menstrual, mid-to-late follicular, ovulatory, early-to-mid luteal, and premenstrual). Significant decreases in CVA were observed from the menstrual to premenstrual (nstudies = 5; nindividuals = 200; d = −1.17, 95% CI (−2.18, −0.17)) and from the mid-to-late follicular to premenstrual phases (nstudies = 8; nindividuals = 280; d = −1.32, 95% CI (−2.35, −0.29)). In conclusion, meta-analyses indicate the presence of CVA fluctuations across the menstrual cycle. Future studies involving CVA should control for cycle phase. Recommendations for covarying or selecting cycle phase are provided.